TARS — Tarsus Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1819790 ·
Last close
$58.52
Market Cap
$2.55B
52W High
$72.50
52W Low
$53.89
ADV30
1,258,719
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 162,054,000 | 152,658,000 | -6,122,000 | -6,967,000 | 581,135,000 | 102,192,000 | 232,184,000 |
| Dec 2025 | 151,668,000 | 140,741,000 | -7,976,000 | -8,373,000 | 562,158,000 | 183,641,000 | 218,732,000 |
| Sep 2025 | 118,697,000 | 110,388,000 | -14,529,000 | -12,585,000 | 534,561,000 | 112,724,000 | 199,479,000 |
| Jun 2025 | 102,660,000 | 96,423,000 | -22,184,000 | -20,340,000 | 494,994,000 | 96,648,000 | 162,382,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,451,000
Investing CF
$-42,115,000
Financing CF
$143,388,000
CapEx
$-9,859,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.62
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-426,628,000
Inventory
$4,372,000
Receivables
$87,109,000
ST Investments
$233,627,000
EBIT TTM
$-56,017,000
Pretax Income TTM
$-64,359,000
Interest Exp TTM
$8,342,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$535,079,008
EBITDA
$-49,018,000
Free Cash Flow
$-21,268,124
Enterprise Value
$2,261,590,528
Total Cash
$388,732,000
Total Debt
$88,676,000
Shares Out
43,631,052
Trailing EPS
$-1.11
Book Value
$8.11
ROE
-14.0%
ROA
-5.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 451,360,000 | -70,969,000 | -66,418,000 | 562,158,000 | 218,732,000 | — | -12,451,000 |
| Dec 2024 | 182,953,000 | -120,569,000 | -115,554,000 | 376,991,000 | 152,457,000 | — | -83,027,000 |
| Dec 2023 | 17,447,000 | -143,158,000 | -135,893,000 | 265,491,000 | 68,503,000 | — | -117,493,000 |
| Dec 2022 | 25,816,000 | -62,712,000 | -62,091,000 | 227,863,000 | 34,963,000 | — | -49,030,000 |
TTM Snapshot
Revenues TTM
$51,229,000
NetIncome TTM
$-100,776,000
OpCashFlow TTM
$0
Assets (Latest)
$376,991,000
Forward EPS
$1.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc. | $2.50B | $40.01 | — |
| BEAM | Beam Therapeutics Inc. | $2.68B | $26.02 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.42B | $9.53 | — |
| VCEL | Vericel Corp | $2.38B | $46.62 | — |
| MEOBF | MESOBLAST LTD | $2.20B | $1.70 | — |
News headlines (Yahoo Finance, 1h cache)
Agenus (AGEN) Earnings Expected to Grow: Should You Buy?
2026-07-30 14:00 · Yahoo
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2026-07-29 14:00 · Yahoo
Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue
2026-07-16 02:11 · Yahoo
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
2026-07-15 20:15 · Yahoo
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
2026-07-13 20:05 · Yahoo
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
2026-07-11 14:02 · Yahoo
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
2026-07-10 08:04 · Yahoo
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
2026-07-08 20:05 · Yahoo
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
2026-07-08 16:00 · Yahoo
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
2026-07-03 09:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.